Niosomes as a novel pharmaceutical formulation encapsulating the hepatoprotective drug silymarin

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 4, Issue 1, 2012, Pages 549-559

  El Ridy, Mohamed S ^a   Badawi, Alia A ^b   Safar, Marwa M ^b   Mohsen, Amira M ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Biochemical; Hepatoprotective; Histopathology; Niosomes; Silymarin

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CARBON TETRACHLORIDE; NIOSOME; SILYMARIN;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG RELEASE; FEMALE; LIVER PROTECTION; NONHUMAN; OXIDATIVE STRESS; PARTICLE SIZE; RAT; SURFACE CHARGE; TRANSMISSION ELECTRON MICROSCOPY;

EID: 84886780736     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Jain, K.K., 'Methods in Molecular Biology', Drug Delivery Systems, Edited by: Kewal K. Jain. Humana Press, Totowa, NJ, 2008; 437.
2. Uchegbu, I.F., Vyas, S.P., Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int. J. Pharm., 1998; 172: 33-70.
3. Uchegbu, I.F., Florence, A.T., Non-ionic surfactant vesicles (niosomes) physical and pharmaceutical chemistry. Adv. Coll. Interf. Sci., 1995; 58: 1-55.
4. D'Souza, S.A., Ray, J., Pandey, S., Udupa, N., Absorption of ciprofloxacin and norfloxacin when adminstered as niosomes-encapsulate,d inclusion complexes. J. Pharm. Pharmacol., 1997; 49: 145-149.
5. Namdeo, A., Jain, N. K., Niosomes as Drug Carriers, Ind. J. Pharm. Sci., 1996; 58: Suppl 2, 41-46.
6. Sahin, N.O., In: Nanomaterials and Nanosystems for Biomedical Applications; Mozafari, M. R.; Ed., Springer: Berlin, 2007: p 67.
7. Ramasamy, K., Agarwal R., Multitargeted therapy of cancer by silymarin Cancer Letters, 2008; 269: 352-362.
8. Wu, J. W., Lin, L. C., Tsai, T. H., Drug-drug interactions of silymarin on the perspective of pharmacokinetics. Journal of Ethnopharmacology, 2009; 121: 181-193.
9. Polyak, S.J., Morishima, C., Lohmannd, V., Pala, S., Leee, D.Y.W., Liue, Y., Graf, T.N., Oberlies, N.F., 2010. Identification of hepatoprotective flavonolignans from silymarin, PNAS, 2010; 107 Suppl 13: 5995-5999.
10. Mourelle, M., Muriel,P., Favari, L., Franco, T., 1989. Prevention of CCl4-induced liver cirrhosis by silymarin. Fundam. Clin. Pharmacol., 1989; 3: 183-191.
11. Muriel, P., Garciapina, T., Perez-Alvarez, V., Mourelle, M., Silymarin protects against paracetamol-induced lipid peroxidation and liver damage. J. Appl. Toxicol., 1992; 12: 439-442.
12. Muriel, P., Mourelle, M., Prevention by silymarin of membrane alterations in acute CCl4 liver damage. J. Appl. Toxicol., 1990; 10: 275-279.
13. Mira, L., Silva, M. and Manso, C. F., Scavenging of reactive oxygen species by silibin dihemisuccinate. Biochem. Pharmacol. 1994; 48: 753-759.
14. Hruby, K.,Csomos,G.,Fuhrmann,M.,Thaler,H., Chemotherapy of Amanita phalloides poisoning with intravenous silibinin.Hum.Toxicol. 1983; 2: 138-195.
15. Desplace, A., Choppin, J., Vogel, G., Trost, W., The effects of silymarin on experimental phalloidine poisoning. Arzneim. Forsch., 1975; 25: 89-96.
16. Sonnenbichler, J., Zetl, I., Biochemical effects of the flavolignane silibinin on RNA, protein and DNA synthesis in rat liver. Prog. Clin. Biol. Res. 1986; 213: 319-331.
17. Juma'a, K.M., Ahmed, Z.A., Numan, I.T., Hussain, S.A., Dose-dependent anti-inflammatory effect of silymarin in experimental animal model of chronic inflammation. African Journal of Pharmacy and Pharmacology, 2009; 3 Suppl 5: 242-247.
18. Fuchs, E.C., Weyhenmeyer, R., Weiner, O.H., Effects of silibinin and of a synthetic analogue on isolated rat hepatic stellate cells and myofibroblasts. Arzneimittelforschung, 1997; 47: 1383-7.
19. Manna, S.K., Mukhopadhyay, A., Van, N.T., Aggarwal B.B., 1999. Silymarin suppresses TNF-induced activation of NF-kappaB, c-jun N-terminal kinase, and apoptosis. Journal of Immunology 1999; 163: 6800-6809.
20. Blumenthal, M., Goldberg, A., Brinkmann, J., Herbal Medicine. Integrative Medicine Communications: Newton, 2000.
21. Giacomelli, S., Gallo, D., Apollonio, P., Ferlini, C., Distefano, M., Morazzoni, P., Riva, A., Bombardelli, E., Mancuso, S. Scambia, G., Silybin and its bioavailable phospholipid complex (IdB 1016) potentiate in vitro and in vivo activity of cisplatin. Life Sci., 2002; 70 Suppl 12: 1447-59.
22. Fraschini, F., Demartini, G., Esposti, D., 2002. Pharmacology of Silymarin. Clin Drug Invest., 2002; 22 Suppl 1: 51-65.
23. Madaus, R., Halbach, G., Trost, W., Salt of silymarin group with aminopolyhydroxy alcohols. US patent 3994925, 1976.
24. Gabetta, B., Bombardelli, E., Pifferi, G., Complexes of flavanolignans with phospholipids, preparation thereof and associated pharmaceutical compositions. US patent 4764508, 1988.
25. Wachter, W., Zaeske, H., Process for the manufacture of flavanolignan preparation with improved release and absorbability, compositions obtainable thereby and their use for the preparation of pharmaceuticals. US patent 6020384, 2000.
26. Kidd, P., Head, K., A review of the bioavailability and clinical efficacy of milk thistle phytosome: A silybin-phosphatidylcholine complex (Siliphos). Altern Med Rev, 2005; 10: 193-203.
27. Li, W., Gao, J., Zhao, H. Z., Liu, C.X., Development of a HPLC-UV assay for silybin-phosphatidylcholine complex (silybinin capsules) and its pharmacokinetic study in healthy male Chinese volunteers. European Journal of Drug Metabolism and Pharmacokinetics, 2006; 31: 265-270.
28. Filburn, C.R., Kettenacker, R., Griffin D.W., Bioavailability of a silybin phosphatidylcholine complex in dogs. Journal of Veterinary Pharmacology and Therapeutics, 2007; 30: 132-138.
29. Valcavi, U., Monterosso, V., Caponi, R., Bosone, E., Wachter, W., Szejtli, J., Inclusion complexes with silybinin, their preparation and pharmaceutical compositions containing them, US patent 5198430, 1993.
30. Giorgi, R., Conti, M., Pifferi, G., Soluble derivative of silybin a method of preparing them and pharmaceutical composition containing them. US patent 4886791, 1999.
31. Azmin, M.N., Florence, A.T., Handjani-Vila, R.M., Stuart, J.F.B., Vanlerberghe, G., Whittaker, J.S., The effect of non-ionic surfactant vesicle (niosome) entrapment on the absorption and distribution of methotrexate in mice. J. Pharm. Pharmacol., 1985; 37: 237-242.
32. Jigar, V., Puja, V., Krutika, S., Formulation and evaluation of topical niosomal gel of erythromycin. Int. J. Pharmacy Pharm. Sci., 2011; 3 Suppl 1: 123-126.
33. Hao, Y., Zhao, F., Li, N., Yang, T., Li, K., Studies on a high encapsulation of colchicine by a noisome system. Int. J. of Pharm., 2002; 244: 73-80.
34. Law, S.L., Lo, W.Y., Lin, M., Increase of liposome stability by incorporation of bovine serum albumin. Drug Dev. Ind. Pharm., 1994; 20: 1411-1423.
35. Fang, J.Y., Yu, S.Y., Wu, P.C., Huang Y.B. and Tsai, Y.H., In vitro skin permeation of estradiol from various proniosome formulations, Int. J. Pharm., 2001; 215 Suppl 1-2: 91-99.
36. O'Neil, M.J., Smith, A., Heckelman, P.E., The Merck Index, 13th ed. Merck and Company, Whitehouse Station, 2001.
37. Aggarwal, D., Kaur, I.P.,. Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system, Int.J. Pharm., 2005; 290 Suppl 1-2: 155-159.
38. Paul,S., Mondol, R., Ranjit, S., Maiti, S., Antilaucomatic niosomal system: recent trend in ocular drug delivery. Int. J. Pharmacy Pharm. Sci., 2010; 2 Suppl 2: 15-18.
39. Liu, T. Guo, R., Investigation of PEG 6000/Tween 80/Span 80/H2O niosome microstructure. Colloid Polym. Sci., 2007; 285: 711-713.
40. Juliano, R.L., Stamp, D., Pharmacokinetics of liposome-encapsulated anti-tumor drugs, Studies with vinblastine, actinomycin D, cytosine arabinoside, and daunomycin. Biochem. Pharmacol., 1978; 27: 21.
41. El-Ridy, M.S., Kassem, M., Akbarieh, M. and Tawashi, R., The effect of surface charge of liposomes on aggregation in the buccal cavity. proceeding 15th Intern. Symp. Control. Rel. Bioact. Mater., Basel, Switzerland, 1988; 344 Suppl 200.
42. Mansour, H.H., Hafez, H.F., Fahmy, N.M., Silymarin Modulates Cisplatin-Induced Oxidative Stress and Hepatotoxicity in Rats. Journal of Biochemistry and Molecular Biology, 2006; 39 Suppl 6: 656-661.
43. Yadav, N. P., Pal, A., Shanker, K., Bawankule, D.U., Gupta, A.K., Darokar, M.P. and Khanuja S. P. S., Synergistic effect of silymarin and standardized extractof Phyllanthus amarus against CCl4-induced hepatotoxicityin Rattus norvegicus. Phytomedicine, 2008; 15: 1053-1061.
44. Devaraj, G.N., Parakh, S.R., Devraj, R., Apte, S.S., Rao, B.R. Rambhau, D., Release studies on niosomes containing fatty alcohols as bilayer stabilizers instead of cholesterol. J Coll. Int, Sci., 2002; 251: 360-365.
45. Manosroi, A., Wongtrakul, P., Manosroi, J., Sakai, H., Sugawara, F., Yuasa, M. , Abe, M., Characterization of vesicles prepared with various non-ionic surfactants mixed with cholesterol. Colloids and Surfaces B: Biointerfaces, 2003; 30: 129-138.
46. Nagarsenker, M.S., Londhea, V.Y., Nadkarnib, G.D., Preparation and evaluation of liposomal formulations of tropicamide for ocular delivery, Int. J. Pharm., 1999; 190 Suppl 1: 63-71.
47. Nagarsenker, M.S., Joshi, A.A., Preparation, Characterization, and Evaluation of Liposomal Dispersions of Lidocaine, Drug Dev. Ind. Pharmacy, 1997; 23 Suppl 12: 1159-1165.
48. Hathout, R.M., Mansour, S., Mortada, N.D., Guinedi, A. S., Liposomes as an Ocular Delivery System for Acetazolamide: In Vitro and In Vivo Studies. AAPS Pharm. Sci. Tech., 2007; 8 Suppl 1, Article 1.
49. Mokhtar, M., Sammour ,O.A., Hammad, M.A., Megrab N.A., Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes, Int. J. Pharm., 2008; 361: 104-111.
50. Baillie, A.J., Florence, A.T., Hume, L.R., Muirhead, G.T., Rogerson, A., The preparation and properties of niosomes-non ionic surfactant vesicles, J. Pharm. Pharmacol., 1985; 37: 863-868.
51. Wissing, S.A., Kayser O. and Müller R. H., Solid lipid nanoparticles for parenteral drug delivery, Advanced Drug Delivery Reviews, 2004; 56 Suppl 9.
52. Namdeo, A., Jain, N.K., Niosomal delivery of 5-flourouracil. J. Microencap., 1999; 16 Suppl 6: 731-740.
53. Rogerson, A., Cummings, J., Florence, A.T., Adriamycin-loaded niosomes-drug entrapment, stability and release. J. Microencap. 1987; 4 Suppl 4: 321-328.
54. Alsarra, I.A., Bosela, A.A., Ahmed, S.M., Mahrous, G.M., Proniosomes as a drug carrier for transdermal delivery of ketorolac, Eur.J. Pharm. Biopharm., 2005; 59 Suppl 3: 485-490.
55. Bayindir, Z.S., Yuksel, A.N., Characterization of Niosomes Prepared With Various Nonionic Surfactants for Paclitaxel Oral Delivery. J. Pharm., Sci., 2010; 99 Suppl 4: 2049-2060.
56. Abdelbary, G., El-gendy, N., Niosome-Encapsulated Gentamicin for Ophthalmic Controlled Delivery, AAPS Pharm. Sci. Tech., 2008; 9 Suppl 3: 740-7.
57. Taylor, K.M.G., Taylor, G., Kellaway, I.W., Stevens, J., Drug entrapment and release from multilamellar and reverse-phase evaporation liposomes. Int. J. Pharm., 1999; 58: 49-55.
58. Vyas, S.P., Singh, R., Asati, R. K., Liposomally encapsulated diclofenac for sonophoresis induced systemic delivery. J. Microencapsulation, 1995; 12: 149-154.
59. McLntosh, T.J., The effect of cholesterol content on the structure of phosphatidylcholine bilayers. Biochim. Biophys. Acta., 1978; 51: 43-58.